ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,708 | -62.6% | 3,784 | -47.0% | 0.00% | – |
| Q2 2023 | $9,920 | +6178.5% | 7,137 | -92.8% | 0.00% | – |
| Q1 2023 | $158 | -72.7% | 99,651 | +7.4% | 0.00% | -100.0% |
| Q4 2022 | $578 | -99.9% | 92,828 | +8.4% | 0.00% | 0.0% |
| Q3 2022 | $574,000 | +19.1% | 85,612 | +13.1% | 0.00% | 0.0% |
| Q2 2022 | $482,000 | +93.6% | 75,713 | +40.9% | 0.00% | – |
| Q1 2022 | $249,000 | +59.6% | 53,717 | +72.5% | 0.00% | – |
| Q4 2021 | $156,000 | -59.1% | 31,133 | -1.5% | 0.00% | -100.0% |
| Q3 2021 | $381,000 | -45.2% | 31,612 | -3.9% | 0.00% | 0.0% |
| Q2 2021 | $695,000 | -22.8% | 32,878 | +2.5% | 0.00% | 0.0% |
| Q1 2021 | $900,000 | -1.0% | 32,071 | -8.2% | 0.00% | 0.0% |
| Q4 2020 | $909,000 | -28.1% | 34,947 | +2.8% | 0.00% | -50.0% |
| Q3 2020 | $1,264,000 | -43.5% | 33,999 | -22.0% | 0.00% | -50.0% |
| Q2 2020 | $2,238,000 | +86.0% | 43,609 | +14.3% | 0.00% | +33.3% |
| Q1 2020 | $1,203,000 | -48.2% | 38,147 | -2.1% | 0.00% | -25.0% |
| Q4 2019 | $2,323,000 | +75.5% | 38,951 | +7.8% | 0.00% | +100.0% |
| Q3 2019 | $1,324,000 | -20.7% | 36,117 | +0.6% | 0.00% | -33.3% |
| Q2 2019 | $1,670,000 | +33.2% | 35,907 | +15.0% | 0.00% | +50.0% |
| Q1 2019 | $1,254,000 | -13.7% | 31,227 | -1.1% | 0.00% | -33.3% |
| Q4 2018 | $1,453,000 | +50.6% | 31,583 | +45.2% | 0.00% | +50.0% |
| Q3 2018 | $965,000 | +6.7% | 21,747 | -5.7% | 0.00% | 0.0% |
| Q2 2018 | $904,000 | -27.3% | 23,061 | +34.1% | 0.00% | -33.3% |
| Q1 2018 | $1,244,000 | +5.3% | 17,194 | -4.1% | 0.00% | +50.0% |
| Q4 2017 | $1,181,000 | +15.0% | 17,934 | -12.5% | 0.00% | 0.0% |
| Q3 2017 | $1,027,000 | +19.7% | 20,500 | +10.6% | 0.00% | 0.0% |
| Q2 2017 | $858,000 | +26.7% | 18,540 | -3.3% | 0.00% | 0.0% |
| Q1 2017 | $677,000 | +230.2% | 19,180 | +17.4% | 0.00% | +100.0% |
| Q4 2016 | $205,000 | -14.6% | 16,334 | -5.8% | 0.00% | 0.0% |
| Q3 2016 | $240,000 | +41.2% | 17,336 | +0.9% | 0.00% | 0.0% |
| Q2 2016 | $170,000 | -25.8% | 17,186 | +27.0% | 0.00% | 0.0% |
| Q1 2016 | $229,000 | -23.4% | 13,529 | +0.6% | 0.00% | 0.0% |
| Q4 2015 | $299,000 | +4.9% | 13,449 | +11.4% | 0.00% | 0.0% |
| Q3 2015 | $285,000 | -69.6% | 12,074 | +5.1% | 0.00% | -66.7% |
| Q2 2015 | $939,000 | +91.6% | 11,485 | +117.1% | 0.00% | +200.0% |
| Q1 2015 | $490,000 | – | 5,290 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |